Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Next Previous
Trial Profile

A Phase 1b Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CB 280 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Sponsors Calithera Biosciences

Most Recent Events

  • 11 Apr 2022 Status changed from recruiting to completed.
  • 31 Mar 2022 According to a Calithera Biosciences media release, enrollment and analysis of all four cohorts is now complete and evaluation of next steps is ongoing.
  • 01 Nov 2021 According to a Calithera Biosciences media release, the study is ongoing with Cohort 4 (300mg BID) on track to complete enrollment by the end of 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top